{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T22:57:10Z","timestamp":1770418630143,"version":"3.49.0"},"reference-count":34,"publisher":"American Society of Hematology","issue":"6","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,3,24]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Patients with indolent conjunctival lymphomas exhibit good prognosis, with exceptional cases of dissemination, and are suitable candidates for intralesional therapies. We report the first prospective phase 2 trial using intralesional rituximab supplemented with autologous serum in adults with relapsed\/refractory indolent CD20+ lymphoma of the conjunctiva (NCT01514344). Patients received 4 weekly intralesional injections of rituximab, followed by 6 monthly injections; 500 \u03bcL of autologous serum was added to rituximab in patients with lymphoma unresponsive to weekly doses. Safety, activity, and antitumor effect of autologous serum were investigated. Twenty patients with mucosa-associated lymphoid tissue (MALT)\u2013type lymphoma were enrolled. Tolerability was excellent, with only 3 mild local reactions. After weekly injections, 11 patients achieved tumor regression, 8 had stable disease, and 1 experienced progressive disease; 9 patients received autologous serum, with response improvement in 4 cases (3 complete responses, 1 partial response). At the end of treatment, 12 patients achieved a complete remission, and 1 achieved a partial response, with an overall response rate of 65% (95% confidence interval, 45-85). At a median follow-up of 42 months (range, 10-78), 12 patients remain relapse free, with 5-year progression-free survival and time-to-next-treatment rates of 59% \u00b1 11% and 69% \u00b1 11%, respectively. Three patients with local relapse were retreated with intralesional rituximab and serum; 2 achieved a complete response that lasted 25+ and 38+ months. Thus, intralesional rituximab is a safe and active therapy in patients with relapsed conjunctival MALT lymphoma. The addition of autologous serum improves response in some cases. Retreatment of local relapses can result in a second durable remission.<\/jats:p>","DOI":"10.1182\/bloodadvances.2020001459","type":"journal-article","created":{"date-parts":[[2020,3,17]],"date-time":"2020-03-17T16:45:31Z","timestamp":1584463531000},"page":"1013-1019","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":15,"title":["Treatment of MALT lymphoma of the conjunctiva with intralesional rituximab supplemented with autologous serum"],"prefix":"10.1182","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9606-6124","authenticated-orcid":false,"given":"Andr\u00e9s J. M.","family":"Ferreri","sequence":"first","affiliation":[{"name":"Lymphoma Unit, Department of Onco-Hematology,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marianna","family":"Sassone","sequence":"first","affiliation":[{"name":"Lymphoma Unit, Department of Onco-Hematology,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabetta","family":"Miserocchi","sequence":"first","affiliation":[{"name":"Ophthalmology Unit, and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Govi","sequence":"first","affiliation":[{"name":"Lymphoma Unit, Department of Onco-Hematology,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caterina","family":"Cecchetti","sequence":"first","affiliation":[{"name":"Lymphoma Unit, Department of Onco-Hematology,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matteo E.","family":"Corti","sequence":"first","affiliation":[{"name":"Pharmacy Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Mappa","sequence":"first","affiliation":[{"name":"Lymphoma Unit, Department of Onco-Hematology,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9504-991X","authenticated-orcid":false,"given":"Luca","family":"Arcaini","sequence":"first","affiliation":[{"name":"Division of Hematology, Fondazione IRCCS Policlinico San Matteo and Department of Molecular Medicine, University of Pavia, Pavia, Italy;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Zaja","sequence":"first","affiliation":[{"name":"Division of Hematology, Azienda Sanitaria Universitaria Integrata di Trieste, Trieste, Italy;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Todeschini","sequence":"first","affiliation":[{"name":"Section of Hematology, Department of Medicine, University of Verona, Verona, Italy;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donato","family":"Mannina","sequence":"first","affiliation":[{"name":"Hematology Unit, Papardo Hospital, Messina, Italy;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa","family":"Calimeri","sequence":"first","affiliation":[{"name":"Lymphoma Unit, Department of Onco-Hematology,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8196-0481","authenticated-orcid":false,"given":"Salvatore","family":"Perrone","sequence":"first","affiliation":[{"name":"Lymphoma Unit, Department of Onco-Hematology,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maurilio","family":"Ponzoni","sequence":"first","affiliation":[{"name":"Pathology Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy; and"},{"name":"Vita e Salute San Raffaele University, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulio","family":"Modorati","sequence":"first","affiliation":[{"name":"Ophthalmology Unit, and"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","published-online":{"date-parts":[[2020,3,17]]},"reference":[{"issue":"38","key":"2020031711395590600_B1","doi-asserted-by":"crossref","first-page":"6524","DOI":"10.1038\/sj.onc.1207843","article-title":"The epidemiology of non-Hodgkin\u2019s lymphoma","volume":"23","author":"Fisher","year":"2004","journal-title":"Oncogene"},{"issue":"13","key":"2020031711395590600_B2","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1093\/jnci\/djj248","article-title":"Rapidly increasing incidence of ocular non-Hodgkin lymphoma","volume":"98","author":"Moslehi","year":"2006","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"2020031711395590600_B3","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1046\/j.1442-9071.2001.d01-18.x","article-title":"Ocular adnexal lymphoproliferative disease: a series of 73 cases","volume":"29","author":"McKelvie","year":"2001","journal-title":"Clin Exp Ophthalmol"},{"issue":"8","key":"2020031711395590600_B4","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1016\/S0161-6420(98)98024-1","article-title":"Lymphoproliferative lesions of the ocular adnexa. Analysis of 112 cases","volume":"105","author":"Coupland","year":"1998","journal-title":"Ophthalmology"},{"issue":"1-2","key":"2020031711395590600_B5","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.beha.2016.11.002","article-title":"Ocular adnexal marginal zone lymphoma: clinical presentation, pathogenesis, diagnosis, prognosis, and treatment","volume":"30","author":"Sassone","year":"2017","journal-title":"Best Pract Res Clin Haematol"},{"issue":"4","key":"2020031711395590600_B6","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1001\/jamaophthalmol.2015.6122","article-title":"Conjunctival lymphoma--an international multicenter retrospective study","volume":"134","author":"Kirkegaard","year":"2016","journal-title":"JAMA Ophthalmol"},{"issue":"8","key":"2020031711395590600_B7","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1517\/14656566.8.8.1073","article-title":"Therapeutic management of ocular adnexal MALT lymphoma","volume":"8","author":"Ferreri","year":"2007","journal-title":"Expert Opin Pharmacother"},{"issue":"24","key":"2020031711395590600_B8","doi-asserted-by":"crossref","first-page":"2988","DOI":"10.1200\/JCO.2011.41.4466","article-title":"Chlamydophila psittaci eradication with doxycycline as first-line targeted therapy for ocular adnexae lymphoma: final results of an international phase II trial","volume":"30","author":"Ferreri","year":"2012","journal-title":"J Clin Oncol"},{"issue":"8","key":"2020031711395590600_B9","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1093\/annonc\/mdv214","article-title":"High-dose clarithromycin is an active monotherapy for patients with relapsed\/refractory extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT): the HD-K phase II trial","volume":"26","author":"Ferreri","year":"2015","journal-title":"Ann Oncol"},{"issue":"1","key":"2020031711395590600_B10","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s10792-007-9102-5","article-title":"Localized conjunctival mucosa-associated lymphoid tissue (MALT) lymphoma is amenable to local chemotherapy","volume":"28","author":"Yu","year":"2008","journal-title":"Int Ophthalmol"},{"issue":"3","key":"2020031711395590600_B11","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S0161-6420(00)00591-1","article-title":"Local chemotherapy with interferon-alpha for conjunctival mucosa-associated lymphoid tissue lymphoma: a preliminary report","volume":"108","author":"Blasi","year":"2001","journal-title":"Ophthalmology"},{"issue":"2","key":"2020031711395590600_B12","first-page":"284","article-title":"Treatment of conjunctival mucosa-associated lymphoid tissue lymphoma with intralesional injection of interferon alfa-2b","volume":"118","author":"Lachapelle","year":"2000","journal-title":"Arch Ophthalmol"},{"issue":"11","key":"2020031711395590600_B13","first-page":"1578","article-title":"Rituximab in patients with mucosal-associated lymphoid tissue-type lymphoma of the ocular adnexa","volume":"90","author":"Ferreri","year":"2005","journal-title":"Haematologica"},{"issue":"5","key":"2020031711395590600_B14","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1182\/blood.V91.5.1644","article-title":"Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies","volume":"91","author":"Shan","year":"1998","journal-title":"Blood"},{"issue":"2","key":"2020031711395590600_B15","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1182\/blood.V83.2.435.435","article-title":"Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20","volume":"83","author":"Reff","year":"1994","journal-title":"Blood"},{"issue":"3","key":"2020031711395590600_B16","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.clml.2013.10.011","article-title":"Clinical characteristics of 95 patients with ocular adnexal and uveal lymphoma: treatment outcomes in extranodal marginal zone subtype","volume":"14","author":"Portell","year":"2014","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"6","key":"2020031711395590600_B17","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1046\/j.1365-2133.2001.04241.x","article-title":"Intralesional rituximab for cutaneous B-cell lymphoma","volume":"144","author":"Paul","year":"2001","journal-title":"Br J Dermatol"},{"issue":"4","key":"2020031711395590600_B18","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1111\/j.1600-0609.2006.00720.x","article-title":"Favorable outcome of primary cutaneous marginal zone lymphoma treated with intralesional rituximab","volume":"77","author":"Kyrtsonis","year":"2006","journal-title":"Eur J Haematol"},{"issue":"1","key":"2020031711395590600_B19","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ophtha.2010.04.036","article-title":"Intralesional rituximab: a new therapeutic approach for patients with conjunctival lymphomas","volume":"118","author":"Ferreri","year":"2011","journal-title":"Ophthalmology"},{"issue":"5","key":"2020031711395590600_B20","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1093\/annonc\/mdl027","article-title":"Clinical implications of hepatitis C virus infection in MALT-type lymphoma of the ocular adnexa","volume":"17","author":"Ferreri","year":"2006","journal-title":"Ann Oncol"},{"issue":"1","key":"2020031711395590600_B21","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/j.1349-7006.2006.00138.x","article-title":"Treatment of primary central nervous system lymphoma with induction of complement-dependent cytotoxicity by intraventricular administration of autologous-serum-supplemented rituximab","volume":"97","author":"Takami","year":"2006","journal-title":"Cancer Sci"},{"key":"2020031711395590600_B22","unstructured":"Ferreri\n              AJ\n            , GuidoboniM, PonzoniM, et al\n          Evidence for association between Chlamydia psittaci infection and ocular adnexal lymphoma (OAL) [abstract].\n          Proc Annu Meet Am Soc Clin Oncol. 2003;22. Abstract 2273."},{"issue":"3","key":"2020031711395590600_B23","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S1053-4296(03)00031-6","article-title":"CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment","volume":"13","author":"Trotti","year":"2003","journal-title":"Semin Radiat Oncol"},{"issue":"5","key":"2020031711395590600_B24","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol"},{"issue":"22","key":"2020031711395590600_B25","doi-asserted-by":"crossref","first-page":"4157","DOI":"10.1200\/JCO.2003.06.085","article-title":"Localized mucosa-associated lymphoid tissue lymphoma treated with radiation therapy has excellent clinical outcome","volume":"21","author":"Tsang","year":"2003","journal-title":"J Clin Oncol"},{"issue":"1","key":"2020031711395590600_B26","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.radonc.2005.11.005","article-title":"Ocular adnexal mucosa-associated lymphoid tissue lymphoma treated with radiotherapy","volume":"78","author":"Ejima","year":"2006","journal-title":"Radiother Oncol"},{"issue":"8","key":"2020031711395590600_B27","doi-asserted-by":"crossref","first-page":"780","DOI":"10.3109\/02713683.2014.959605","article-title":"Systemic rituximab immunotherapy in the management of primary ocular adnexal lymphoma: single institution experience","volume":"40","author":"Tuncer","year":"2015","journal-title":"Curr Eye Res"},{"issue":"40","key":"2020031711395590600_B28","doi-asserted-by":"crossref","first-page":"68583","DOI":"10.18632\/oncotarget.19788","article-title":"Frontline treatment with chemoimmunotherapy for limited-stage ocular adnexal MALT lymphoma with adverse factors: a phase II study","volume":"8","author":"Kim","year":"2017","journal-title":"Oncotarget"},{"issue":"2","key":"2020031711395590600_B29","doi-asserted-by":"crossref","first-page":"575","DOI":"10.4143\/crt.2017.182","article-title":"Low-dose radiation therapy for primary conjunctival marginal zone B-cell lymphoma","volume":"50","author":"Lee","year":"2018","journal-title":"Cancer Res Treat"},{"issue":"4","key":"2020031711395590600_B30","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/ceo.12184","article-title":"Long-term outcomes after adjunctive topical 5-flurouracil or mitomycin C for the treatment of surgically excised, localized ocular surface squamous neoplasia","volume":"42","author":"Bahrami","year":"2014","journal-title":"Clin Exp Ophthalmol"},{"issue":"3","key":"2020031711395590600_B31","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.ophtha.2011.09.008","article-title":"Intralesional interferon-\u03b1 for conjunctival mucosa-associated lymphoid tissue lymphoma: long-term results","volume":"119","author":"Blasi","year":"2012","journal-title":"Ophthalmology"},{"issue":"7","key":"2020031711395590600_B32","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1007\/s00432-013-1438-9","article-title":"Long-term outcomes of primary ocular adnexal lymphoma treatment with intraorbital rituximab injections","volume":"139","author":"Savino","year":"2013","journal-title":"J Cancer Res Clin Oncol"},{"issue":"7","key":"2020031711395590600_B33","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.oftal.2016.11.004","article-title":"Intralesional rituximab in primary conjunctival follicular lymphoma relapsed","volume":"92","author":"Rodr\u00edguez Villa","year":"2017","journal-title":"Arch Soc Esp Oftalmol"},{"issue":"5","key":"2020031711395590600_B34","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.leukres.2011.01.030","article-title":"Intralesional administration of rituximab for treatment of CD20 positive orbital lymphoma: safety and efficacy evaluation","volume":"35","author":"Laurenti","year":"2011","journal-title":"Leuk Res"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/6\/1013\/1719276\/advancesadv2020001459.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/6\/1013\/1719276\/advancesadv2020001459.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,17]],"date-time":"2020-03-17T16:45:55Z","timestamp":1584463555000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/4\/6\/1013\/452700\/Treatment-of-MALT-lymphoma-of-the-conjunctiva-with"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,17]]},"references-count":34,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,3,24]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2020001459","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,17]]}}}